FAQ/Help |
Calendar |
Search |
Today's Posts |
![]() |
#1 | ||
|
|||
Member
|
|
||
![]() |
![]() |
"Thanks for this!" says: | kiwi33 (01-16-2020), soccertese (01-13-2020) |
![]() |
#2 | ||
|
|||
Magnate
|
THAT'S quite an article.
|
||
![]() |
![]() |
![]() |
#3 | ||
|
|||
Member
|
Yes indeed ... and here is the first update!
Simon wrote: "We are looking forward to seeing the results of [the AIM-PD Ambroxol] study published early in 2020." ... and here are those results: CPT article: Ambroxol in Parkinson's: Results of Phase ll Trial Published Ambroxol in Parkinson's: Results of Phase ll Trial Published | The Cure Parkinson's Trust Research paper: Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations - A Nonrandomized, Noncontrolled Trial Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial | Genetics and Genomics | JAMA Neurology | JAMA Network (hat tip to Parkinsonjisung at HU for the links) |
||
![]() |
![]() |
![]() |
#4 | |||
|
||||
Grand Magnate
|
Thanks jeffreyn for providing the excellent summary.
__________________
Knowledge is power. |
|||
![]() |
![]() |
Reply |
Thread Tools | |
Display Modes | |
|
|
![]() |
||||
Thread | Forum | |||